Low-dose tacrolimus (FK506)-based immunosuppressive protocol in living donor renal transplantation

Transplant International

Volumn 11, Issue SUPPL. 1, 1998, Pages

  Kokado, Y ^a   Takahara, S ^a   Kyo, M ^a   Ichimaru, N ^a   Jing Ding, W ^a   Miki, T ^a   Okuyama, A ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

FK506; Low dose; Renal transplantation; Tacrolimus

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ARTICLE; CLINICAL TRIAL; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; INCIDENCE; KIDNEY TRANSPLANTATION; LIVING DONOR;

CYCLOSPORINE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; LIVING DONORS; TACROLIMUS;

EID: 0003093673     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1432-2277.1998.tb01197.x     Document Type: Article

References (15)

1. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Kohsaka M, Aoki H, Imanaka H (1987) FK-506, a novel immunosuppressant isolated from a streptomyces. J Antibiot (Tokyo) 40: 1249-1255
2. Ochiai T, Nakajima K, Nagara M, Suzuki T, Asano T, Uematsu T, Goto T, Hori S, Kenmochi T, Nakagoori T, Isono K (1987) Effect of a new immunosuppressive agent, FK-506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc 19: 1284-1286
3. Jensen CWB, Jordan ML, Schneck FX, Shapio R, Tzakis A, Hakaia TR, Starzl TE (1991) Pediatric renal transplantation under FK506 immunosuppression. Transplant Proc 23: 3075-3077
4. Japanese FK506 Study Group (1991) Clinicopathological evaluation of kidney transplants in patients given a fixed dose of FK-506. Transplant Proc 23: 3111-3115
5. Starzl TE, Fung JJ, Jordan M, Sapiro R, Tzakis A, McCauley J, Johnston J, Iwaki Y, Jain A, Alessiani M, Todo S (1990) Kidney transplantation under FK 506. JAMA 264: 63-67
6. McCauly J, Takaya S, Fung JJ, Tzakis A, Abu-Elmagd K, Jain A, Todo S, Starzl TE (1991) The question of FK 506 nephrotoxicity after liver transplantation. Transplant Proc 23: 1444-1447
7. Starzl TE, Abu-Elmagd K, Tzakis A, Fung JJ, Porter KA, Todo S (1991) Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "Forbidden Organs", side effects mechanisms, and practical pharmacokinetics. Transplant Proc 23: 914-919
8. Shapiro R, Fung JJ, Jain AB, Parks P, Todo S, Starzl TE (1990) The side effects of FK 506 in humans. Transplant Proc 22 (suppl 1): 35-36
9. Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Joean M, Jensen C, Hakaia T (1991) New onset of diabetes in FK 506 vs cyclosporine-treated kidney. Transplant Proc 23: 3169-3170
10. Randhawa RS, Sapiro R, Jordan ML, Starzl TE, Demetris AJ (1993) The histopathological changes associated with allograft rejection and drug toxicity and renal transplant recipients maintained on FK 506. Am J Surg Pathol 17: 60-68
11. Japanese FK 506 Study Group (1993) Japanese study of FK 506 on kidney transplantation: results of late phase II study. Transplant Proc 25: 649-654
12. Japanese FK 506 Study Group (1993) Transplant Proc 25: 624
13. Japanese FK 506 Study Group (Yokoyama I, Uchida K, Fukao K, Ochiai T, Takahashi K, Endo T, Oshima S, Ishibashi M, Takahara S, Ota K, Takagi H, Sonoda T) (1995) FK 506: long-term study in kidney transplantation. Transplant Proc 27: 818-821
14. Japanese FK 506 Study Group (Yokoyama I, Uchida K, Fukao K, Ochiai T, Takahashi K, Endo T, Oshima S, Ishibashi M, Takahara S, Ota K, Takagi H, Sonoda T) (1995) FK 506: long-term study in kidney transplantation. Transplant Proc 27: 818-821
15. Japanese FK 506 Study Group (Ochiai T, Fukao K, Takahashi K, Endo T, Oshima S, Uchida K, Yokoyama I, Ishibashi M, Takahara S, Iwasaki Y, Ota K, Takagi H, Sonoda T) (1995) Phase III study of FK 506 in kidney transplantation. Transplant Proc 27: 829-833